USPTO appeals panel cements key claims position in antibody case

ARP maintained rejection of two claims of Xencor’s antibodies patent application | Panel clarified specification for means-plus-function claim limitations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

USPTO veteran joins Finnegan as of counsel in Washington, DC

2 May 2024 Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.

Biotechnology

USPTO hands win to Daiichi Sankyo in cancer drug dispute

18 January 2024 The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.

More on this story

Careers

USPTO veteran joins Finnegan as of counsel in Washington, DC

2 May 2024 Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.

Biotechnology

USPTO hands win to Daiichi Sankyo in cancer drug dispute

More on this story

Careers

USPTO veteran joins Finnegan as of counsel in Washington, DC

2 May 2024 Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.

Biotechnology

USPTO hands win to Daiichi Sankyo in cancer drug dispute